German chamomile (Matricaria chamomilla L.) is a traditional aromatic medicinal plant, its flower contains volatile aromatic oil (essential oil). The main sesquiterpene components of the essential oil are (E)-β-farnesene, chamazulene, and α-bisabolol, these components have significant medicinal value and are used in food, cosmetics, and pharmaceuticals. However, the German chamomile genome has not yet been cataloged in any database; consequently, research on the intricate regulatory network and interaction mechanisms among proteins in German chamomile remains limited. Furthermore, no study has thus far developed a yeast cDNA library for German chamomile. Therefore, we constructed a homogenized yeast cDNA library using different tissues of German chamomile, this yeast cDNA library had a titer of 1.444 × 10⁸ colony-forming units/mL, an average insert size of > 1,000 bp, and a positive rate of 100%. In addition, 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (HDS) that interacted with Hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase (HDR) involved in the final step of the methylerythritol 4-phosphate (MEP) pathway was verified through the yeast two-hybrid (Y2H) assay and bimolecular fluorescence complementation (BiFC). At the same time, the expression pattern and function of McHDS were further analyzed. In conclusion, we successfully constructed a yeast cDNA library of German chamomile for the first time, and McHDS interacting with McHDRa/b was successfully screened, providing a reliable theoretical foundation for investigating the molecular mechanism of its coordination with McHDRa/b to regulate the biosynthesis of (E)-β-farnesene in German chamomile. Which lays the groundwork for our comprehensive understanding of the protein interaction network involved in sesquiterpene synthesis of German chamomile.

2025-07-24·International Journal of Medical Sciences

Alpha-bisabolol protects against neonatal asthma by suppressing airway inflammatory signaling

Article

作者: Lee, Seungho ; Thiruvengadam, Rekha ; Govindarasu, Mydhili ; Khaled, Jamal Mohammed Ali ; Kim, Jin Hee

Objective: This study aimed to evaluate the anti-inflammatory effects of alpha-bisabolol (AB) in allergic airway inflammation-induced rat pups. Methods: We evaluated the anti-adverse effects of AB against allergic airway inflammation-induced male Wistar rat pups, with four categorized groups including vehicle-controls (group 1), controls treated with 25 mg/kg of AB (group 2), allergic airway inflammation-induced cases (group 3), and cases treated with 25 mg/kg of AB before allergic airway inflammation induction (group 4). Lung histopathology, bronchoalveolar lavage fluid eosinophils, and several inflammatory markers were also examined in each group. Results: AB significantly decreased mucous gland hypertrophy, eosinophil infiltration, and oxidative stress marker levels in the allergic airway inflammation-induced AB-pretreated rats. Moreover, AB pretreatment significantly reduced the levels of proinflammatory cytokines, such as interleukin (IL)-1β, IL-6, IL-8, IL-17, monocyte chemoattractant protein-1, C-X-C chemokine receptor type 4 (CXCR4), and thymic stromal lymphopoietin, which were increased in allergic airway inflammation-induced cases. Furthermore, transcription of cyclooxygenase-2, tumor necrosis factor-α, CXCR4, toll-like receptor 4, Eotaxin-1, and regulated upon activation normal T cell expressed and secreted were significantly suppressed in allergic airway inflammation-induced AB-pretreated rats. Conclusions: These results indicate that AB can protect against neonatal asthma by inhibiting acute or chronic inflammation induced during disease onset.

2025-07-01·EUROPEAN JOURNAL OF PHARMACOLOGY

Exploring the mechanism of α-Bisabolol in the treatment of psoriasis based on network pharmacology and experimental validation

Article

作者: Wu, Yixing ; Yang, Huiwen ; Liu, Bing ; Wang, Yan ; You, Tianhui ; Yuan, Shaoying ; Zhang, Yan ; Ye, Zhiming

This study aims to evaluate the effects of α-Bisabolol in the treatment of psoriasis both in vivo and in vitro, and to elucidate its mechanism of action. We used network pharmacology to explore the potential active components and targets of α-Bisabolol in the treatment of psoriasis. Psoriasis-like models were induced in mice or keratinocytes using imiquimod (IMQ) or tumor necrosis factor-α (TNF-α). The results indicated that α-Bisabolol shares 133 potential genes with psoriasis, and pathway enrichment analysis showed that the PI3K/AKT and nuclear factor κB (NF-κB) signaling pathways are considered key pathways. In vivo experiments showed that α-Bisabolol reduced epidermal thickening, inflammatory cell infiltration, and histological psoriasis-like lesions in IMQ-induced mice (P < 0.05, P < 0.01). α-Bisabolol inhibited the elevation of inflammatory cytokines (including interleukin-6(IL-6), interleukin-1β(IL-1β), interleukin-17A(IL-17A), interleukin-23(IL-23) and tumor necrosis factor-α (TNF-α)) in skin lesions of mice and TNF-α-treated HaCat cells (P < 0.05, P < 0.01). Mechanistically, α-Bisabolol inhibited the phosphorylation of PI3K/AKT (PI3K and AKT) and NF-κB (IκB and p65) signaling pathways activated by IMQ (P < 0.05, P < 0.01). Similar changes were detected in TNF-α-treated HaCaT cells. This suggests that α-Bisabolol may inhibit inflammation in TNF-α-treated keratinocytes and psoriasis mice through the PI3K/AKT and NF-κB pathways, providing a new theoretical basis for clinical application in the treatment of psoriasis.

100 项与 α-Bisabolol 相关的药物交易

登录后查看更多信息